Antithetical activation of both GIP and GLP-1 receptors has offered a promising approach for the treatment of metabolic conditions due to their combined effects in enhancing insulin secretion, reducing energy consumption, and improving insulin sensitivity both directly and indirectly compared to GLP-1 receptor mono-agonism [45, 57]
"And preferably, we also should need that evidence publicly funded, rather than coming from drug studies that are funded by drug companies," he said
This CNS access appears to be GLP1 receptordependent, because it was not observed in GLP1RKO mice (Secher et al., 2014)
It may upregulate serotonin signaling, offering possible neuroprotective benefits and improving mood and cognition [13]
risk ratio 1.9, 95% CI 1.2-3.1)